DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...
Antibody-based therapies are used to treat numerous diseases, from cancer to rheumatic disorders and multiple sclerosis.
OmniAb, Inc. (NASDAQ: OABI) announces the launch of its new OmniUltra™ platform, the industry’s first and only transgenic ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved additional indications for its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary ...
The latest announcement is out from MindWalk Holdings ( (HYFT) ).
MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab ...
EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publication of a study titled Immunogenicity Risk Assessment of Peptide- ...
Event Title: MindWalk Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 https://events.q4inc.com/attendee/410261259 ...
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the publication in Nature ...
Detailed price information for Mersana Therapeutics Inc (MRSN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback